Summary
Guardant Health, Inc. reported a significant increase in total revenue for the second quarter and first half of 2024, driven primarily by its Precision Oncology Testing segment. Total revenue for the three months ended June 30, 2024, rose by 29% year-over-year to $177.2 million, and for the six months ended June 30, 2024, revenue grew by 30% to $345.7 million. Despite revenue growth, the company continued to incur substantial net losses, with a loss of $102.6 million for the quarter and $217.6 million for the first half of the year. This is a key area for investors to monitor, as is the company's substantial cash balance of $1.0 billion as of June 30, 2024, which provides a sufficient runway for more than 12 months. A significant development during the period was the FDA approval and subsequent commercial launch of the Shield blood test for colorectal cancer screening in August 2024, positioning Guardant Health as a leader in early cancer detection.
Financial Highlights
53 data points| Revenue | $177.24M |
| Cost of Revenue | $72.42M |
| Gross Profit | $104.81M |
| R&D Expenses | $83.10M |
| Operating Expenses | $277.85M |
| Operating Income | -$100.62M |
| Interest Expense | $645K |
| Net Income | -$102.63M |
| EPS (Basic) | $-0.84 |
| EPS (Diluted) | $-0.84 |
| Shares Outstanding (Basic) | 122.45M |
| Shares Outstanding (Diluted) | 122.45M |
Key Highlights
- 1Total revenue increased by 29% to $177.2 million for Q2 2024 and by 30% to $345.7 million for the first half of 2024, driven by strong performance in Precision Oncology Testing.
- 2Precision Oncology Testing revenue grew by 33% in Q2 and 35% in the first half, with both clinical and biopharmaceutical customer segments showing robust growth.
- 3The company reported a net loss of $102.6 million for Q2 2024 and $217.6 million for the first half of 2024, underscoring continued investment in growth and development.
- 4Guardant Health ended the period with a strong liquidity position, holding $1.0 billion in cash, cash equivalents, and restricted cash, providing over 12 months of operating runway.
- 5The Shield blood test received FDA approval in July 2024 and became commercially available in August 2024 for colorectal cancer screening, marking a significant milestone in early cancer detection.
- 6Research and Development expenses decreased by 8% year-over-year for Q2 and 9% for the first half, largely due to reduced clinical study costs.
- 7Sales and Marketing expenses increased by 15% in Q2 and 10% in the first half, reflecting investments in commercial infrastructure and marketing for new product launches.